Dergiler / KONURALP TIP DERGİSİ / 2026 / Volume: 18 Issue: 3

The De Ritis Ratio (AST/ALT) and Its Diagnostic Relevance in ISUP Grade Reclassification After Prostatectomy

Mustafa Kemal Kaya(İnegöl State Hospital)0000-0002-0231-8288
Dursun Baba(Düzce University, Faculty of Medicine, Department of Urology)0000-0002-4779-6777
Sayfa
—
Yayın Tarihi
2026-10-27
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Further prospective studies are warranted to clarify its potential supplementary clinical value.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: The prognostic value of the De Ritis ratio (AST/ALT) in localized prostate cancer remains uncertain.
📊
Temel Bulgular & Veri:Material and Methods: This retrospective study included 152 patients who underwent radical prostatectomy for prostate adenocarcinoma between 2012 and 2022.
💡
Sonuç & Katkı:Further prospective studies are warranted to clarify its potential supplementary clinical value.
🔬Tür:Research Article
📍Kapsam:2012 Verileri
⚙️Değişkenler:Prostate cancer · De Ritis Ratio · AST/ALT

Abstract

Aim: The prognostic value of the De Ritis ratio (AST/ALT) in localized prostate cancer remains uncertain. This study evaluated its predictive role in International Society of Urological Pathology (ISUP) grade upgrading and adverse pathological features following radical prostatectomy. Material and Methods: This retrospective study included 152 patients who underwent radical prostatectomy for prostate adenocarcinoma between 2012 and 2022. The De Ritis ratio was calculated using preoperative AST and ALT levels. Patients were grouped according to ISUP grade upgrading between biopsy and final pathology. Receiver operating characteristic (ROC) analysis and multivariate logistic regression were performed. Results: ISUP upgrading occurred in 46.3% of patients. Mean De Ritis ratios did not differ significantly between groups (p = 0.38). However, a ratio ≤1.22 was associated with higher upgrading rates (51.5% vs. 34.7%, p = 0.05). ROC analysis demonstrated limited discriminatory ability (AUC = 0.552; sensitivity 75%, specificity 39%). Multivariate analysis identified age (p = 0.02), prostate volume (p = 0.048), and biopsy ISUP grade (p = 0.001) as independent predictors, whereas the De Ritis ratio was not independently associated with upgrading. Conclusions: The De Ritis ratio was not an independent predictor of ISUP upgrading, although associations with adverse pathological features were observed. Its limited discriminatory performance suggests that it should not be used as a standalone predictor. Further prospective studies are warranted to clarify its potential supplementary clinical value.

🔖

Bu Makaleye Atıf Yap

Kaya, M. K., Baba, D. (2026). The De Ritis Ratio (AST/ALT) and Its Diagnostic Relevance in ISUP Grade Reclassification After Prostatectomy. KONURALP TIP DERGİSİ, Volume: 18 Issue: 3. https://doi.org/10.18521/ktd.1892184

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (29)

  1. Cao J. Effect of immune checkpoint inhibitors on advanced prostate cancer: a meta-analysis. Arch Esp Urol. 2025;78(2):194-206. doi:10.56434/j.arch.esp.urol.20257802.27.
  2. Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27(17):5730. doi:10.3390/molecules27175730.
  3. Morote J, Paesano N, Picola N, Muñoz-Rodriguez J, Ruiz-Plazas X, Muñoz-Rivero MV, et al. The role of digital rectal examination for early detection of significant prostate cancer in the era of magnetic resonance imaging. Life (Basel). 2024;14(11):1359. doi:10.3390/life14111359.
  4. Bujaldon JM, Vitagliano GJ, Blas L, Vocos MM, Pita HR. Freehand transperineal prostate biopsy improves the detection rate of clinically significant prostate cancer. Urol Res Pract. 2025;50(5):269. doi:10.5152/tud.2025.24026.
  5. De Ritis F, Mallucci L, Coltorti M, Giusti G, Caldera M. Anicteric virus hepatitis in a closed environment as shown by serum transaminase activity. Bull World Health Organ. 1959;20(4):589-602.
  6. Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y, et al. Tumor biomarkers for diagnosis, prognosis and targeted therapy. Signal transduction and targeted therapy. 2024;9(1):132. doi:10.1038/s41392-024-01823-2.
  7. Nazari M, Babakhanzadeh E, Mollazadeh A, Ahmadzade M, Mohammadi Soleimani E, Hajimaqsoudi E. HOTAIR in cancer: Diagnostic, prognostic, and therapeutic perspectives. Cancer Cell Int. 2024;24(1):415. doi:10.1186/s12935-024-03612-x.
  8. Chen W, Wang W, Zhou L, Zhou J, He L, Li J, et al. Elevated AST/ALT ratio is associated with all‐cause mortality and cancer incident. Journal of clinical laboratory analysis. 2022;36(5):e24356. doi:10.1002/jcla.24356.
  9. Karatas M, Keles N, Parsova KE, Ciftci HO, Ozkok S, Kahraman E, et al. High AST/ALT ratio is associated with cardiac involvement in acute COVID-19 patients. Medicina (Kaunas). 2023;59(6):1163. doi:10.3390/medicina59061163.
  10. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. doi:10.1158/2159-8290.CD-21-1059.
  11. Wu T, Zheng Z, Wang J, He M, Wang J, Pan Y, et al. Systemic inflammation score using pretherapeutic inflammatory markers to predict prognosis for hepatocellular carcinoma patients after hepatic arterial infusion chemotherapy. J Hepatocell Carcinoma. 2023:2133-45. doi:10.2147/JHC.S437329.
  12. Bijalwan P, Pooleri GK, Kalavampara SV, Bhat S, Thomas A, Sundar P, et al. Pathological outcomes and biochemical recurrence-free survival after radical prostatectomy for high-risk prostate cancer in the Indian population. Indian J Urol. 2018;34(4):260-7. doi:10.4103/iju.IJU_65_18.
  13. Nkengurutse G, Tian F, Jiang S, Wang Q, Wang Y, Sun W. Preoperative predictors of biochemical recurrence-free survival in high-risk prostate cancer following radical prostatectomy. Front Oncol. 2020;10:1761. doi:10.3389/fonc.2020.01761.
  14. Beauval J-B, Roumiguié M, Filleron T, Benoit T, de la Taille A, Malavaud B, et al. Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer. BMC Urol. 2016;16(1):26. doi:10.1186/s12894-016-0146-6.
  15. Momo F, Hoque M, Sarkar S, Faysal M, Mitu S, Suchi S. Comparison of serum alanine aminotransferase and aspartate aminotransferase among obese and non-obese adults. Mymensingh Med J. 2024;33(4):955-61.
  16. İnan R, Bitkin A, Aydın M, Küçük E, Atilla MK, İrkilata L. Preoperative De Ritis Ratio for the evaluation of recurrence and progression in non-muscle invasive bladder cancer. Bull Urooncol. 2023;22(1):15-9. doi:10.4274/uob.galenos.2022.2022.1.2.
  17. Ndrepepa G. De Ritis ratio and cardiovascular disease: evidence and underlying mechanisms. J Lab Precis Med. 2023;8:1-24. doi:10.21037/jlpm-22-68.
  18. Shaikh SM, Varma A, Kumar S, Acharya S, Patil R. Navigating disease management: a comprehensive review of the De Ritis Ratio in clinical medicine. Cureus. 2024;16(7):e64447. doi:10.7759/cureus.64447.
  19. Taştemur S, Şenel S, Kasap Y, Odabaş Ö. Effectiveness of de ritis (AST/ALT) ratio in predicting biochemical recurrence in patients underwent radical prostatectomy for localized prostate cancer. Eur J Ther. 2022;28(1):8-13. doi:10.54614/eurjther.2022.0038.
  20. Wang H, Fang K, Zhang J, Jiang Y, Wang G, Zhang H, et al. The significance of De Ritis (aspartate transaminase/alanine transaminase) ratio in predicting pathological outcomes and prognosis in localized prostate cancer patients. Int Urol Nephrol. 2017;49(8):1391-8. doi:10.1007/s11255-017-1618-7.
  21. Cho YH, Hwang JE, Chung HS, Kim MS, Hwang EC, Jung SI, et al. The De Ritis (aspartate transaminase/alanine transaminase) ratio as a predictor of oncological outcomes in patients after surgery for upper urinary tract urothelial carcinoma. Int Urol Nephrol. 2017;49(8):1383-90. doi:10.1007/s11255-017-1613-z.
  22. Mori K, Janisch F, Mostafaei H, Kimura S, Lysenko I, Karakiewicz PI, et al., editors. Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy. Urol Oncol. 2020;38(6)601.e17-24. doi:10.1016/j.urolonc.2020.02.008.
  23. Madeddu C, Busquets S, Donisi C, Lai E, Pretta A, López-Soriano FJ, et al. Effect of cancer-related cachexia and associated changes in nutritional status, inflammatory status, and muscle mass on immunotherapy efficacy and survival in patients with advanced non-small cell lung cancer. Cancers. 2023;15(4):1076. doi:10.3390/cancers15041076.
  24. Vaughan VC, Martin P, Lewandowski PA. Cancer cachexia: impact, mechanisms and emerging treatments. J Cachexia Sarcopenia Muscle. 2013;4(2):95-109. doi:10.1007/s13539-012-0087-1.
  25. Ndrepepa G, Holdenrieder S, Kastrati A. Prognostic value of De Ritis ratio in patients with acute myocardial infarction. Clinica Chimica Acta. 2022;535:75-81. doi:10.1016/j.cca.2022.08.016.
  26. Hewton KG, Johal AS, Parker SJ. Transporters at the interface between cytosolic and mitochondrial amino acid metabolism. Metabolites. 2021;11(2):112. doi:10.3390/metabo11020112.
  27. Lee H, Choi YH, Sung HH, Han DH, Jeon HG, Jeong BC, et al. De Ritis ratio (AST/ALT) as a significant prognostic factor in patients with upper tract urothelial cancer treated with surgery. Clinical genitourinary cancer. 2017;15(3):e379-85. doi:10.1016/j.clgc.2016.08.023.
  28. Arıkan MG, Ecer G, Şahin MF, Hereklioğlu S, Gökalp F, Arda E, et al. Prognostic role of tumor percentage in multiparametric MRI for upgrade prediction before radical prostatectomy. Bull Urooncol. 2024;23(1):36-41. doi:10.4274/uob.galenos.2024.2023.7.1.
  29. Smani S, Sundaresan V, Lokeshwar SD, Choksi AU, Carbonella J, Brito J, et al. Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. Explor Target Antitumor Ther. 2024;5(4):981-96. doi:10.37349/etat.2024.00259.